Pivotal bioVenture Partners
SlowingFiled to raiseGrand Cayman, Cayman IslandsLast fund filed 2021
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Pivotal bioVenture Partners CNS Fund I SLP | August 2021 | Indefinite | $1.1M | 6 |
| Pivotal bioVenture Partners CNS Fund IFiled to raise in 2021, with no closing reported yet. | 2021 | Indefinite | $0 | 0 |
| Pivotal bioVenture Partners Fund II SLPFiled to raise in 2021, with no closing reported yet. | 2021 | Indefinite | $0 | 0 |
| Pivotal bioVenture Partners Fund IIFiled to raise in 2021, with no closing reported yet. | 2021 | Indefinite | $0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
3 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Peter Bisgaard | Slowing | Biotech & pharma, Medical devices | 12 |
Classified sectors of Pivotal bioVenture Partners’s own portfolio companies, based on 12 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Pivotal bioVenture Partners’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| NEA | 3 | Ceterix Orthopaedics, Eargo, Ra Pharmaceuticals |
| Vivo Innovation | 2 | Bolt Biotherapeutics, Outpost Medicine |
| Capra CLO Founders | 1 | Bolt Biotherapeutics |
| Maveron | 1 |
| 0 |
| Pivotal bioVenture Partners Fund I | 2017 | Indefinite | $298M | 5 |
| 1 |
| Kin Ho KwokNot on the current fund | Quiet | None listed | 0 | 0 |
| Vincent Sai Sing Cheung | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| Eargo |
| Passage BIO Inc | 1 | Outpost Medicine |
| Sofinnova Venture Partners | 1 | Bolt Biotherapeutics |
| SV Life Sciences | 1 | THESAN PHARMACEUTICALS |
| TCG Crossover | 1 | Outpost Medicine |
| Tcgx Asia Life Sciences | 1 | Outpost Medicine |
| Versant Venture Capital | 1 | Ceterix Orthopaedics |
| Virtuoso-mccarran | 1 | THESAN PHARMACEUTICALS |
| Westlake Biopartners | 1 | Ceterix Orthopaedics |
A shared board seat: a company where filings name a Pivotal bioVenture Partners partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.